10/16/2015 - 10:09am

Last month’s launch of the first generic biologic drug in the United States is the first step in a movement that some say could drive down the nation’s healthcare bill and bring new treatment options to thousands of patients across the country.

10/15/2015 - 2:34pm

 Feds are probing the drug maker on drug pricing, distribution and patient assistance programs, according to the Wall Street Journal. “The company’s drug pricing has drawn scrutiny from doctors, hospitals and Democrats in Congress after The Wall Street Journal reported in April about how it and some other companies buy and then significantly raise the prices of drugs,” the report says. (Wall Street Journal, registration required)

10/15/2015 - 10:44am

The New Jersey legislation requires the Department of Health to post a link on its website containing a list of products in which dextromethorphan is an active ingredient. 

10/14/2015 - 4:02pm

NACDS’ Carol Kelly has been nominated for an advocacy award given by the Professional Women in Advocacy Conference. 

10/05/2015 - 11:43am

The Generic Pharceutical Association’s CEO and President Chip Davis offered his recommendations for the Trans-Pacific Partnership. 

10/01/2015 - 10:48am

With the release of Congress’ Conference Report for the National Defense Authorization Acts come concerns over the bill’s impact on TRICARE beneficiaries. 

09/30/2015 - 2:59pm

As the Center for Medicare and Medicaid services rolled out its plan for an Enhanced Medication Therapy Management model for pharmacies, KPMG’s Larry Kocot published a blog post for Health Affairs expanding on the announcement. “These changes are designed to better align the standalone prescription drug plan (“PDP”) sponsor and government financial interests, while also creating incentives for more robust investment and innovation in targeting medication therapy interventions,“ Kocot wrote. (Health Affairs)

09/29/2015 - 12:26pm

The Centers for Medicare and Medicaid Services has outlined its latest model for medication therapy management that it hopes will increase adherence and improve outcomes among Medicare Part D beneficiaries. 

09/28/2015 - 11:11am

Under the terms of the consent decree, the company will not be allowed to manufacture or sell dietary supplement products until the FDA has determined that the business is in compliance.